PURPOSE: The Bethesda guidelines suggest to perform microsatellite instability (MSI) test in early onset rectal cancer and not in patients>50 years with proximal colon cancer. The aim of the study was to evaluate whether the risk of high MSI (MSI-H) is greater in proximal colon cancer of patients 51-60 years old than in early-onset rectal cancer. METHODS: Consecutive colorectal cancer (CRC) patients were evaluated. Tumor location, cancer family history, MSI status and histology were recorded. Mutations in MLH1/MSH2 were investigated in MSI-H tumors. Patients were subdivided into groups: group A, proximal colon cancer patients 51-60 years old and groups B, C and D, patients<or=50 years old, with rectal cancer, proximal and distal colon cancer, respectively. RESULTS: Out of 409 CRC patients evaluated, 48 (12%) showed tumors with MSI-H. No MSI-H tumors were found in distal and rectal tumors of patients at sixth decade of life. Group A included 27 patients, eight (29.7%) MSI-H cancers, four missense mutations in MLH1/MSH2; groups B, C and D included 26, 11 and 11 patients with two (7.7%), two (18%) and two (18%) MSI-H cancers, respectively. One missense mutation on MSH2 in group B, one pathogenetic mutation on MSH1 in group C and one pathogenetic mutation on MSH2 in group D were found. Tumors of group A showed an increased probability to have MSI-H if compared to those of group B (OD=4.907, p=0.043). CONCLUSIONS: The Bethesda criteria should be broadened to include patients 51-60 years old with proximal colon cancer.
PURPOSE: The Bethesda guidelines suggest to perform microsatellite instability (MSI) test in early onset rectal cancer and not in patients>50 years with proximal colon cancer. The aim of the study was to evaluate whether the risk of high MSI (MSI-H) is greater in proximal colon cancer of patients 51-60 years old than in early-onset rectal cancer. METHODS: Consecutive colorectal cancer (CRC) patients were evaluated. Tumor location, cancer family history, MSI status and histology were recorded. Mutations in MLH1/MSH2 were investigated in MSI-H tumors. Patients were subdivided into groups: group A, proximal colon cancerpatients 51-60 years old and groups B, C and D, patients<or=50 years old, with rectal cancer, proximal and distal colon cancer, respectively. RESULTS: Out of 409 CRCpatients evaluated, 48 (12%) showed tumors with MSI-H. No MSI-H tumors were found in distal and rectal tumors of patients at sixth decade of life. Group A included 27 patients, eight (29.7%) MSI-H cancers, four missense mutations in MLH1/MSH2; groups B, C and D included 26, 11 and 11 patients with two (7.7%), two (18%) and two (18%) MSI-H cancers, respectively. One missense mutation on MSH2 in group B, one pathogenetic mutation on MSH1 in group C and one pathogenetic mutation on MSH2 in group D were found. Tumors of group A showed an increased probability to have MSI-H if compared to those of group B (OD=4.907, p=0.043). CONCLUSIONS: The Bethesda criteria should be broadened to include patients 51-60 years old with proximal colon cancer.
Authors: Paolo Peterlongo; Nandita Mitra; Ana Sanchez de Abajo; Miguel de la Hoya; Chiara Bassi; Lucio Bertario; Paolo Radice; Emily Glogowski; Khedoudja Nafa; Trinidad Caldes; Kenneth Offit; Nathan A Ellis Journal: Carcinogenesis Date: 2006-06-14 Impact factor: 4.944
Authors: J G Park; H F Vasen; K J Park; P Peltomaki; M Ponz de Leon; M A Rodriguez-Bigas; J Lubinski; N E Beck; M L Bisgaard; M Miyaki; J T Wijnen; S Baba; H T Lynch Journal: Dis Colon Rectum Date: 1999-06 Impact factor: 4.585
Authors: Heather Hampel; Wendy L Frankel; Edward Martin; Mark Arnold; Karamjit Khanduja; Philip Kuebler; Hidewaki Nakagawa; Kaisa Sotamaa; Thomas W Prior; Judith Westman; Jenny Panescu; Dan Fix; Janet Lockman; Ilene Comeras; Albert de la Chapelle Journal: N Engl J Med Date: 2005-05-05 Impact factor: 91.245
Authors: Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava Journal: J Natl Cancer Inst Date: 2004-02-18 Impact factor: 13.506
Authors: Bikash Devaraj; Aaron Lee; Betty L Cabrera; Katsumi Miyai; Linda Luo; Sonia Ramamoorthy; Temitope Keku; Robert S Sandler; Kathleen L McGuire; John M Carethers Journal: J Gastrointest Surg Date: 2010-09-16 Impact factor: 3.452
Authors: Sang Jin Kim; Hyoung Ran Kim; Seok Hyung Kim; Ji Hye Han; Yong Beom Cho; Seong Hyeon Yun; Woo Yong Lee; Hee Cheol Kim Journal: Ann Surg Treat Res Date: 2014-08-26 Impact factor: 1.859